FIG 7.

BA71ΔCD2 protects against Georgia 2007/1 heterologous challenge. The degrees of protection afforded by the different doses of BA71ΔCD2 were evaluated after Georgia 2007/1 lethal challenge by monitoring the proportion of surviving pigs left in each group (A) and by comparing the kinetics of fever (B), viremia (C), and ASFV nasal secretion (D). Data plotted in panels B, C, and D correspond to individual animals, and fever, viremia, and nasal secretion were monitored not only after Georgia 2007/1 challenge but also from the day of BA71ΔCD2 immunization. The proportion of pigs with fever and/or ASFV positive, before and/or after challenge, is shown in parentheses. Control, challenge control (discontinuous lines).